Somatic retinoblastoma 1 (RB1) loss is prevalent across different cancer types and is enriched in treatment‐refractory tumors, such as castration‐resistant prostate cancer (CRPC) and small‐cell lung cancer, but cannot be considered as a direct druggable target. This evidence concerns the gene RB1 and cancer.